spironolactone has been researched along with Lung Injury, Acute in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the therapeutic/preventive potential of liposome-encapsulated spironolactone (SP; Lipo-SP) for acute lung injury (ALI) and fibrosis." | 7.83 | Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice. ( Ji, WJ; Li, YM; Lin, ZC; Ma, YQ; Su, CC; Wang, PP; Wei, LQ; Xiang, GA; Zhang, L; Zhang, MP; Zhang, X; Zhang, YD; Zhang, Z; Zhou, X, 2016) |
| "This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)." | 7.76 | The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010) |
| "Spironolactone pretreatment markedly reduced intestinal I/R-induced lung injury as indicated by histology and MDA and MPO levels." | 5.43 | Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. ( Aktunc, E; Barut, F; Ozacmak, VH; Sayan-Ozacmak, H; Turan, I, 2016) |
| "To examine the therapeutic/preventive potential of liposome-encapsulated spironolactone (SP; Lipo-SP) for acute lung injury (ALI) and fibrosis." | 3.83 | Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice. ( Ji, WJ; Li, YM; Lin, ZC; Ma, YQ; Su, CC; Wang, PP; Wei, LQ; Xiang, GA; Zhang, L; Zhang, MP; Zhang, X; Zhang, YD; Zhang, Z; Zhou, X, 2016) |
| "This study aimed to test the feasibility of spironolactone treatment in comparison with a surfactant in the early stage of acute respiratory distress syndrome (ARDS) in rats, as assessed by the acute lung injury (ALI) score, blood gas, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)." | 3.76 | The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. ( Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS, 2010) |
| "Spironolactone pretreatment markedly reduced intestinal I/R-induced lung injury as indicated by histology and MDA and MPO levels." | 1.43 | Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. ( Aktunc, E; Barut, F; Ozacmak, VH; Sayan-Ozacmak, H; Turan, I, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, WJ | 2 |
| Ma, YQ | 2 |
| Zhou, X | 2 |
| Zhang, YD | 2 |
| Lu, RY | 1 |
| Guo, ZZ | 1 |
| Sun, HY | 1 |
| Hu, DC | 1 |
| Yang, GH | 1 |
| Li, YM | 2 |
| Wei, LQ | 2 |
| Barut, F | 1 |
| Ozacmak, VH | 1 |
| Turan, I | 1 |
| Sayan-Ozacmak, H | 1 |
| Aktunc, E | 1 |
| Zhang, X | 1 |
| Zhang, L | 1 |
| Su, CC | 1 |
| Xiang, GA | 1 |
| Zhang, MP | 1 |
| Lin, ZC | 1 |
| Wang, PP | 1 |
| Zhang, Z | 1 |
| Atalay, C | 1 |
| Dogan, N | 1 |
| Aykan, S | 1 |
| Gundogdu, C | 1 |
| Keles, MS | 1 |
4 other studies available for spironolactone and Lung Injury, Acute
| Article | Year |
|---|---|
Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.
Topics: Acute Lung Injury; Animals; Antigens, CD; Antigens, Ly; Bleomycin; Bronchoalveolar Lavage Fluid; Che | 2013 |
Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats.
Topics: Acute Lung Injury; Animals; Intestinal Diseases; Male; Rats; Rats, Wistar; Reperfusion Injury; Spiro | 2016 |
Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bleomycin; Cell Polarity; Humans; Liposomes; M | 2016 |
The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats.
Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Disease Models, Animal; Lung; Male; Mineralocorticoi | 2010 |